Edwards Lifesciences Corporation (EW)
USD 72.81
(-1.77%)
USD 72.81
(-1.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.09 Billion USD | 15.22% |
| 2022 | 2.51 Billion USD | 4.84% |
| 2021 | 2.39 Billion USD | 20.5% |
| 2020 | 1.98 Billion USD | -0.29% |
| 2019 | 1.99 Billion USD | 16.61% |
| 2018 | 1.71 Billion USD | 11.28% |
| 2017 | 1.53 Billion USD | 14.04% |
| 2016 | 1.34 Billion USD | 9.26% |
| 2015 | 1.23 Billion USD | 2.43% |
| 2014 | 1.2 Billion USD | 12.72% |
| 2013 | 1.06 Billion USD | 7.22% |
| 2012 | 996.6 Million USD | 12.14% |
| 2011 | 888.7 Million USD | 17.8% |
| 2010 | 754.4 Million USD | 10.24% |
| 2009 | 684.3 Million USD | 6.29% |
| 2008 | 643.8 Million USD | 19.16% |
| 2007 | 540.3 Million USD | 10.22% |
| 2006 | 490.2 Million USD | 9.49% |
| 2005 | 447.7 Million USD | 10.03% |
| 2004 | 406.9 Million USD | 12.19% |
| 2003 | 362.7 Million USD | 2.81% |
| 2002 | 352.8 Million USD | 2.56% |
| 2001 | 344 Million USD | 20.28% |
| 2000 | 286 Million USD | -11.18% |
| 1999 | 322 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 776.3 Million USD | 3.67% |
| 2024 Q3 | 698.5 Million USD | -3.44% |
| 2024 Q2 | 723.4 Million USD | -6.81% |
| 2023 Q3 | 709.9 Million USD | -3.94% |
| 2023 Q4 | 748.8 Million USD | 5.48% |
| 2023 FY | 2.89 Billion USD | 15.22% |
| 2023 Q1 | 697.5 Million USD | 8.44% |
| 2023 Q2 | 739 Million USD | 5.95% |
| 2022 Q1 | 598.9 Million USD | -8.82% |
| 2022 FY | 2.51 Billion USD | 4.84% |
| 2022 Q3 | 610.9 Million USD | -7.41% |
| 2022 Q2 | 659.8 Million USD | 10.17% |
| 2022 Q4 | 643.2 Million USD | 5.29% |
| 2021 FY | 2.39 Billion USD | 20.5% |
| 2021 Q1 | 537.8 Million USD | 0.67% |
| 2021 Q3 | 602.4 Million USD | 0.43% |
| 2021 Q2 | 599.8 Million USD | 11.53% |
| 2021 Q4 | 656.8 Million USD | 9.03% |
| 2020 Q2 | 457 Million USD | -7.71% |
| 2020 Q1 | 495.2 Million USD | -8.48% |
| 2020 Q4 | 534.2 Million USD | 6.27% |
| 2020 Q3 | 502.7 Million USD | 10.0% |
| 2020 FY | 1.98 Billion USD | -0.29% |
| 2019 Q4 | 541.1 Million USD | 7.85% |
| 2019 Q1 | 451.7 Million USD | 0.11% |
| 2019 Q2 | 500.4 Million USD | 10.78% |
| 2019 Q3 | 501.7 Million USD | 0.26% |
| 2019 FY | 1.99 Billion USD | 16.61% |
| 2018 Q3 | 431.3 Million USD | 0.54% |
| 2018 FY | 1.71 Billion USD | 11.28% |
| 2018 Q2 | 429 Million USD | 7.46% |
| 2018 Q1 | 399.2 Million USD | -3.41% |
| 2018 Q4 | 451.2 Million USD | 4.61% |
| 2017 Q1 | 358.3 Million USD | 2.81% |
| 2017 FY | 1.53 Billion USD | 14.04% |
| 2017 Q4 | 413.3 Million USD | 6.66% |
| 2017 Q2 | 378.2 Million USD | 5.55% |
| 2017 Q3 | 387.5 Million USD | 2.46% |
| 2016 Q3 | 342.7 Million USD | 0.29% |
| 2016 Q2 | 341.7 Million USD | 8.44% |
| 2016 Q4 | 348.5 Million USD | 1.69% |
| 2016 Q1 | 315.1 Million USD | -1.68% |
| 2016 FY | 1.34 Billion USD | 9.26% |
| 2015 FY | 1.23 Billion USD | 2.43% |
| 2015 Q4 | 320.5 Million USD | 2.4% |
| 2015 Q2 | 311.4 Million USD | 7.79% |
| 2015 Q3 | 313 Million USD | 0.51% |
| 2015 Q1 | 288.9 Million USD | -5.93% |
| 2014 Q4 | 307.1 Million USD | -0.87% |
| 2014 Q3 | 309.8 Million USD | 1.71% |
| 2014 FY | 1.2 Billion USD | 12.72% |
| 2014 Q2 | 304.6 Million USD | 7.63% |
| 2014 Q1 | 283 Million USD | 5.17% |
| 2013 Q2 | 269.9 Million USD | 1.85% |
| 2013 FY | 1.06 Billion USD | 7.22% |
| 2013 Q4 | 269.1 Million USD | 1.7% |
| 2013 Q3 | 264.6 Million USD | -1.96% |
| 2013 Q1 | 265 Million USD | 4.83% |
| 2012 Q2 | 256.4 Million USD | 4.31% |
| 2012 Q1 | 245.8 Million USD | 9.68% |
| 2012 Q3 | 241.6 Million USD | -5.77% |
| 2012 FY | 996.6 Million USD | 12.14% |
| 2012 Q4 | 252.8 Million USD | 4.64% |
| 2011 Q3 | 227.2 Million USD | -0.39% |
| 2011 Q4 | 224.1 Million USD | -1.36% |
| 2011 Q1 | 209.3 Million USD | 5.55% |
| 2011 FY | 888.7 Million USD | 17.8% |
| 2011 Q2 | 228.1 Million USD | 8.98% |
| 2010 Q4 | 198.3 Million USD | 6.79% |
| 2010 FY | 754.4 Million USD | 10.24% |
| 2010 Q1 | 179.2 Million USD | -0.78% |
| 2010 Q2 | 191.2 Million USD | 6.7% |
| 2010 Q3 | 185.7 Million USD | -2.88% |
| 2009 FY | 684.3 Million USD | 6.29% |
| 2009 Q4 | 180.6 Million USD | 5.86% |
| 2009 Q3 | 170.6 Million USD | -0.29% |
| 2009 Q2 | 171.1 Million USD | 5.75% |
| 2009 Q1 | 161.8 Million USD | 3.72% |
| 2008 Q2 | 161.9 Million USD | 1.7% |
| 2008 FY | 643.8 Million USD | 19.16% |
| 2008 Q4 | 156 Million USD | 1.04% |
| 2008 Q3 | 154.4 Million USD | -4.63% |
| 2008 Q1 | 159.2 Million USD | 7.57% |
| 2007 Q2 | 130.8 Million USD | 3.56% |
| 2007 Q3 | 134.1 Million USD | 2.52% |
| 2007 Q1 | 126.3 Million USD | 0.96% |
| 2007 Q4 | 148 Million USD | 10.37% |
| 2007 FY | 540.3 Million USD | 10.22% |
| 2006 Q1 | 98 Million USD | -13.2% |
| 2006 Q2 | 125.9 Million USD | 28.47% |
| 2006 FY | 490.2 Million USD | 9.49% |
| 2006 Q3 | 119.8 Million USD | -4.85% |
| 2006 Q4 | 125.1 Million USD | 4.42% |
| 2005 Q4 | 112.9 Million USD | 2.73% |
| 2005 Q1 | 110.3 Million USD | 3.96% |
| 2005 Q2 | 114.3 Million USD | 3.63% |
| 2005 Q3 | 109.9 Million USD | -3.85% |
| 2005 FY | 447.7 Million USD | 10.03% |
| 2004 Q2 | 101.7 Million USD | -9.92% |
| 2004 FY | 406.9 Million USD | 12.19% |
| 2004 Q4 | 106.1 Million USD | 4.43% |
| 2004 Q3 | 101.6 Million USD | -0.1% |
| 2004 Q1 | 112.9 Million USD | 23.79% |
| 2003 Q4 | 91.2 Million USD | 4.47% |
| 2003 Q1 | 90.4 Million USD | 4.63% |
| 2003 Q2 | 97.1 Million USD | 7.41% |
| 2003 Q3 | 87.3 Million USD | -10.09% |
| 2003 FY | 362.7 Million USD | 2.81% |
| 2002 FY | 352.8 Million USD | 2.56% |
| 2002 Q2 | 67.3 Million USD | 8.03% |
| 2002 Q4 | 86.4 Million USD | -36.84% |
| 2002 Q3 | 136.8 Million USD | 103.27% |
| 2002 Q1 | 62.3 Million USD | -3.71% |
| 2001 Q2 | 150.5 Million USD | 119.07% |
| 2001 Q3 | 60.1 Million USD | -60.07% |
| 2001 FY | 344 Million USD | 20.28% |
| 2001 Q4 | 64.7 Million USD | 7.65% |
| 2001 Q1 | 68.7 Million USD | 146.24% |
| 2000 FY | 286 Million USD | -11.18% |
| 2000 Q1 | 95 Million USD | 10.47% |
| 2000 Q2 | 96 Million USD | 1.05% |
| 2000 Q3 | 74.9 Million USD | -21.98% |
| 2000 Q4 | 27.9 Million USD | -62.75% |
| 1999 FY | 322 Million USD | 0.0% |
| 1999 Q4 | 86 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Abbott Laboratories | 15.71 Billion USD | 80.328% |
| Allurion Technologies Inc. | 120.57 Million USD | -2463.467% |
| Artivion, Inc. | 223.43 Million USD | -1283.362% |
| Avanos Medical, Inc. | 375.5 Million USD | -723.142% |
| Butterfly Network, Inc. | 162.46 Million USD | -1802.49% |
| Butterfly Network, Inc. | 162.46 Million USD | -1802.49% |
| Bio-Rad Laboratories, Inc. | 1.04 Billion USD | -195.06% |
| Boston Scientific Corporation | 7.47 Billion USD | 58.667% |
| Perspective Therapeutics, Inc. | 17.42 Million USD | -17637.289% |
| CONMED Corporation | 564.24 Million USD | -447.797% |
| Paragon 28, Inc. | 210.1 Million USD | -1371.157% |
| Glaukos Corporation | 367.83 Million USD | -740.293% |
| Globus Medical, Inc. | 887.16 Million USD | -248.404% |
| Inspire Medical Systems, Inc. | 568.49 Million USD | -443.7% |
| Integer Holdings Corporation | 250.95 Million USD | -1131.635% |
| Medtronic plc | 16.12 Billion USD | 80.836% |
| Nevro Corp. | 389.36 Million USD | -693.825% |
| Owlet, Inc. | 51.21 Million USD | -5934.675% |
| Penumbra, Inc. | 590.87 Million USD | -423.104% |
| Vicarious Surgical Inc. | 80.66 Million USD | -3731.726% |
| Smith & Nephew plc | 3.46 Billion USD | 10.848% |
| Sonendo, Inc. | 68.46 Million USD | -4414.569% |
| STERIS plc | 1.4 Billion USD | -120.721% |
| Stryker Corporation | 9.2 Billion USD | 66.436% |
| Vapotherm, Inc. | 66.02 Million USD | -4581.409% |
| Zimmer Biomet Holdings, Inc. | 3.27 Billion USD | 5.65% |